To be printed on hospital headed paper

Ethics Approval Ref: 14/NW/0035

PATIENT INFORMATION SHEET

Version 1.2, 10th February 2014

Study name: REQUITE (Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality-of-life in cancer survivors)

Dear Patient,

You are invited to take part in a research study. We would like to explain to you why the research is being done and what it will involve for you. Please take time to read the following information carefully and discuss it with others if you wish. Please ask us if anything is not clear or if you need more information. Take time to decide if you wish to take part.

What is the purpose of this study?

The purpose of this study is to try to predict which patients who receive radiotherapy are more likely to have side effects than others. Approximately half of all cancer patients receive radiotherapy as part of their cancer treatment. The dose of radiation given, however, is limited because of a risk of damaging the healthy cells that surround the tumour. Patients vary in how they react to radiation. About 5% of patients (5 out of every 100) are sensitive and at risk of having side effects. In recent years, researchers have developed predictive models and biological tests to try to identify before the start of treatment those patients who are very sensitive. However, these methods are not yet ready to use in the clinic so radiation doses for all patients are currently limited by the doses the most sensitive patients can have. The international REQUITE multi-centre observational study is the largest study of its kind, and the information collected will allow researchers to thoroughly test these models and biological markers for future use. We hope that results from this study will confirm and/or improve current predictive models and biological tests to predict how a patient will respond to radiotherapy. If we are successful, then in future we could identify the 'radiosensitive' patients before they start their radiotherapy. The sensitive patients could potentially be safely and effectively treated with less radiation and other patients with more radiation. This should reduce side effects for all patients, improve quality of life and potentially increase the number of patients successfully treated for their cancer.

Why have I been chosen?
You are invited to take part in this study because you were recently diagnosed with cancer and your doctor has recommended that you should receive radiotherapy. The REQUITE study needs 5,300 patients in total to take part. We want to include patients with breast, prostate or lung cancer. REQUITE is a worldwide study with patients from Belgium, France, Germany, Italy, Spain, The Netherlands, UK and USA.

Do I have to take part?
No, it is entirely voluntary. If you decide to take part, please keep this information sheet and sign a consent form to show you agree to participate. We will also ask your permission to tell your family doctor that you are taking part in the study. If you do take part, you can withdraw at any time and without giving a reason. A decision to withdraw, or a decision not to take part, will not affect in any way your treatment or the standard of care you receive now or in the future.

What will happen to me if I do take part?
If you decide to take part in this study, you will be seen by a member of the research team at the beginning of your cancer treatment who will then ask you to complete some questionnaires asking about symptoms you may be experiencing before you start your radiotherapy treatment and about your general well-being. You will then be asked to complete the same questionnaires again when your radiotherapy is finished and then at routine follow-up appointments at least once a year for at least two years after your treatment. This is a practical and reliable way for us to measure and record the effects of your radiotherapy treatment. These questionnaires should preferably be completed in the clinic (but could be done at home) and take no more than 20 minutes to complete each time.

We will also ask you to give a blood sample. We would like to take a maximum 30ml of blood, which is less than three tablespoons and similar to the amount taken for routine blood-testing. If possible, we will collect the sample when you are already having blood taken as part of your standard treatment at your usual follow up appointments. Apart from the short time involved and the minimal discomfort associated with giving blood, there should be no pain, distress or inconvenience caused to you by taking part in the REQUITE study. Your blood sample will be coded using a unique study number so that no one outside the study can identify you from it. A portion of the sample will be stored in the REQUITE Biobank in the UK ready for the subsequent research work including genetics analysis and the remainder will be stored locally. The results of these tests will not be fed back to you or your doctor.

If you are receiving treatment for breast cancer, we may ask your permission to have digital photographs taken of your breasts (your face will not be included). This will take place at the start of your treatment, and will be repeated at your two year follow up appointment to assess any changes. Your research doctor or nurse will discuss this with you.

It may be possible to use your blood sample for other tests in the future. We would like to store your sample for future medical research on this or a related project. With your

permission, the side effects information, imaging scans and photographs (where applicable) could also be used anonymously (linked with a unique study identifier) in future studies. Future research may be carried out at academic institutions, hospitals or by commercial companies involved in cancer research worldwide. Please be aware that this could mean that doctors and scientists in other countries might use your blood sample and medical data. However, the data will not contain any personal information so you could not be identified. Please read the section below called '*Will my taking part in the study be kept confidential?*' All new research work planning to make use of samples and/or data will be subject to ethical approval and also require approval from the REQUITE Steering Committee.

The REQUITE research team will also look at your medical data to collect information on your cancer and your treatment. The information will be used to test predictive models for radiotherapy toxicity.

Would participating in this study be of any benefit to me?
There will be no direct benefit to you.

Would participating in this study be harmful to me?
REQUITE is an observational study so your treatment will not change by choosing to take part in this study. As indicated above, you will be asked to complete some questionnaires and to give a blood sample. If you feel any discomfort or distress by taking part in this research study, please speak with a member of your research team. If it is appropriate, and with your expressed consent, they will be able to refer you to the relevant services for further support. Potential harms of taking blood are a large bruise (haematoma) or extremely rarely impairment of nerves. If you are harmed by taking part in this research project, there are no special compensation arrangements. If you are harmed due to someone's negligence, then you might have grounds for a legal action but you may have to pay for it.

How can I complain?
If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions. If they are unable to resolve your concern or you wish to make a complaint regarding the study, please contact a University Research Practice and Governance Co-ordinator on 0161 275 7583 or 0161 275 8093 or by email to research.complaints@manchester.ac.uk.

Will my taking part in the study be kept confidential?
All information will be kept strictly confidential and your name will not appear on any publications resulting from the study. Your medical notes will be seen by authorised members of the research team at your local hospital so that they can collect information needed for the REQUITE study. You will be given a unique REQUITE study number, which will be used together with your initials and date of birth on any forms that the research staff fill in. Samples will be coded with the unique REQUITE study number and kept anonymously which means that the laboratory researchers who are carrying out any tests on your sample cannot identify

you. All information about you will be treated as strictly confidential and nothing that might identify you will be revealed to any third party.

Selected scientific and medical employees of the study co-ordinator (German Cancer Research Center) and sponsor (The University of Manchester) and those conducting the study with them, may need to examine your medical records to ensure the study is being run properly and that the information collected on the forms is correct. Your confidentiality will be protected at all times.

We would like to be able to make your blood sample and information available to other researchers to use in future medical research beyond the end of the REQUITE study. Any other research study planning to make use of your sample or information must be approved by an independent research ethics committee before it is allowed to go ahead. Any samples and information transferred to other researchers will not contain your personal information, so they will not be able to identify you from the information provided.

What happens to my samples and information if I decide to withdraw?

You can withdraw at any time and without giving a reason. If you decide to withdraw your coded blood samples and information will be retained for use in this study and for future medical research unless you specifically request otherwise. If you want your blood sample to be destroyed and/ or your information not to be used in the future for research purposes, please inform a member of your research team. This can either be a verbal request or in writing. We will then organize for your samples to be destroyed and your medical information removed from the REQUITE database.

How will I know the results of the study?

A member of the research team will be able to provide hard copies of newsletters and other relevant material to those who wish to keep up-to-date with progress and the results of the study. When the study is complete, the results will be published in medical and scientific journals and also presented at medical and scientific meetings. All data are anonymised (i.e. your name will not be disclosed in journals or at presentations). The REQUITE website (www.requite.eu) will also provide background to the study and up-to-date information on recruitment for both patients and the public alike.

Who is organising and funding the research?

This study is being carried out by a network of medical doctors and scientists from across the world. This is an international study co-ordinated by Professor Catharine West at The University of Manchester in the UK and Professor Jenny Chang-Claude at the German Cancer Research Center in Germany. It is funded by the European Commission's FP7 HEALTH programme. The study Sponsor is The University of Manchester. The local study leader in the UK is Professor Catharine West at The University of Manchester.

Who has reviewed this study?

This research has been reviewed by an independent group of people on a Research Ethics Committee to protect your safety, rights, wellbeing and dignity. The Greater Manchester East Research Ethics Committee has reviewed the study and agreed it may go ahead.

What should I do now?

It is up to you to decide whether to take part. Please think about what the study involves and discuss it with your friends and family. Your research doctor or nurse will be happy to answer any questions you might have. When you decide, please let your research doctor or nurse know. You will be asked to sign a consent form and will be given a copy to keep together with this information sheet. Please keep these safe. If, at any time, you have any questions about the study you can contact the REQUITE research doctor or nurse using the details below.

Research Doctor/ Nurse: <*Site specific*>
Telephone number: <*Site specific*>
E-mail: <*Site specific*>

Thank you for considering helping with our research.